. Author manuscript; available in PMC: 2014 Aug 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):572–577. doi: 10.1097/QAI.0b013e31829308f8

Table 2b.

Summary of minor mutations detected with consensus sequencing of plasma RNA one month after HAART cessation.

Drug class association	Minor resistance mutations detected	Frequency of mutation (%)		Frequency in treatment naïve HIV-1 subtype C patients¹⁷ (%)
Drug class association	Minor resistance mutations detected	PI Arm ZDV/3TC/LPV/r	NRTI Arm ZDV/3TC/ABC	Frequency in treatment naïve HIV-1 subtype C patients¹⁷ (%)
PI	L10I	1/25 (4.0)	1/29 (3.4)	(2.1)
	L10V	1/25 (4.0)	0/29 (0.0)	(1.4)
	Q58E	1/25 (4.0)	0/29 (0.0)	(0.3)
	A71V	1/25 (4.0)	0/29 (0.0)	(0.2)
	A71T	3/25 (12.0)	1/29 (3.4)	(1.0)
	T74S	2/25 (8.0)	0/29 (0.0)	(9.7)
NRTI	V118I	0/25 (0.0)	2/29 (6.9)	(2.1)
NNRTI	E138A	2/25 (8.0)	2/29 (6.9)	(5.0)